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ABSTRACT
MAD family proteins are transcriptional repressors
that antagonize the functions of MYC oncoproteins.
In particular, MAD1 has been demonstrated to
interfere with MYC-induced proliferation, transfor-
mation and apoptosis. The MAD1 gene is expressed
in distinct patterns, mainly associated with differ-
entiation and quiescence. We observed that MAD1
is directly activated by G-CSF in promyelocytic cell
lines. To investigate the transcriptional regulation
of the human MAD1 gene, we have cloned and
characterized its promoter. A region of high homol-
ogy between the MAD1 orthologs of human, mouse
and rat contains the core promoter, marked by open
chromatin, high GC content and the lack of a TATA
box. Using deletion constructs we identified two
CCAAT-boxes occupied by C/EBPa and b in the
homology region that mediate responsiveness to
G-CSF receptor signaling. The necessary signals
include the activation of STAT3 and the RAS/RAF/
ERK pathway. STAT3 does not bind directly
to promoter DNA, but is recruited by C/EBPb.
In summary, our studies provide a first analysis of
the MAD1 promoter and suggest STAT3 functions
as a C/EBPb cofactor in the regulation of the
MAD1 gene. Our findings provide the base for the
characterization of additional signal transduction
pathways that control the expression of MAD1.
INTRODUCTION
The transcription factors of the MYC/MAX/MAD net-
work have evolved as critical regulators of many aspects
of cell physiology, including proliferation, diﬀerentiation
and apoptosis. Furthermore, extensive work documents
that MYC functions as an oncoprotein both in human
tumors and animal models (1–4). The proteins of this
network form dimeric complexes containing one MAX
protein and one member of the MYC or MAD group of
proteins or MAX itself. Dimer formation is a prerequisite
for sequence-speciﬁc DNA binding, both being mediated
by the bHLHZip domains, highly conserved regions
common to all MYC/MAX/MAD network members (5).
In general, DNA-bound MYC/MAX heterodimers acti-
vate gene transcription by recruiting a number of diﬀerent
cofactors, including diﬀerent histone acetyl transferases,
that regulate chromatin and polymerase function (1,6).
MYC/MAX complexes bind to DNA sequences with the
consensus 50-CACGTG-30, referred to as E-boxes. These
elements are also recognized by MAD/MAX heterodimers
and at least in vitro little diﬀerence in the binding
speciﬁcity between MYC/MAX and MAD/MAX com-
plexes could be observed (5). These ﬁndings suggest that
the diﬀerent dimers compete for binding to speciﬁc DNA
sites. This model is particularly attractive since MAD
proteins have been shown to recruit corepressor com-
plexes with histone deacetylase activity (7). Thus, not only
can MYC/MAX and MAD/MAX complexes compete for
DNA binding but they also recruit opposing cofactor
functions to target genes. In summary, these ﬁndings
indicate that activating MYC/MAX and repressing
MAD/MAX complexes are part of a switch mechanism
that regulates the activities mentioned at the beginning.
The MAD group of proteins consists of six members, the
four highly related small MAD1, MXI1 (MAD2), MAD3
and MAD4, and the considerably larger MNT and MGA
(7). It has been suggested earlier on that these proteins
might function as tumor suppressors since they can
antagonize MYC function. Indeed, tissue culture transfor-
mation assays demonstrated that MAD proteins interfere
with MYC-dependent transformation (8–16). Further-
more mxi1
–/– mice exhibit an increased susceptibility to
tumor formation (17). However, despite extensive eﬀort,
little evidence has been obtained to support the tumor
suppressor notion for human tumors. This lack of evidence
might be, at least in part, due to the rather broad
expression pattern of all MAD genes and proteins,
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eliminated during tumorigenesis (7). In addition to eﬀects
on transformation, MAD1 has been implicated in control-
ling aspects of proliferation, diﬀerentiation and apoptosis
(9,18–23). The latter is at least in part due to the repression
of the PTEN gene by MAD1 (24). This results in the
activation of the AKT kinase and subsequently inhibition
of apoptosis. In addition, ectopic expression of MAD1 in
mice resulted in early postnatal lethality and dwarﬁsm (25).
Of particular importance are the studies in mice with
a targeted disruption of mad1 (26). Although the overall
phenotype was rather mild, in the absence of Mad1
granulopoiesis is distorted. While the number of mature
granulocytes is unaltered, the precursor cells undergo extra
rounds of cell division prior to terminal diﬀerentiation and
the mature cells are highly susceptible to apoptosis (26).
Consistent with this latter ﬁnding, granulocytes of mad1
transgenic animals are more resistant to apoptotic condi-
tions (25). Together, these studies provide evidence for
important regulatory functions of MAD proteins.
The available expression studies suggest that the small
MAD genes are transcribed preferentially during prolif-
eration arrest and diﬀerentiation (7). Speciﬁcally, MAD1
expression has been documented in diﬀerentiating hema-
topoietic cells as well as a number of additional cell types
(16,19,21,26–33). Together, these ﬁndings suggest that
the MAD1 gene must be the target of a number of distinct
signaling pathways that control the expression of this gene
in the diﬀerent cell types. Previously, we have observed
that MAD1 expression can be activated in human
promyelocytic cell lines by diﬀerent stimuli, including
the phorbol ester TPA and retinoic acid, that induce
diﬀerentiation (29,30). In addition, the cytokine granulo-
cyte-colony stimulating factor (G-CSF) was capable of
enhancing MAD1 expression (32). G-CSF is a key
cytokine to regulate the proliferation and survival of
myeloid progenitor cells and to stimulate their diﬀerentia-
tion and maturation toward granulocytes (34–36). The
G-CSF receptor (G-CSFR) activates multiple signaling
pathways, similar to other cytokine receptors, that
include the JAK/STAT and the RAS/RAF/MAPK path-
ways (37–41). G-CSF regulates a large set of genes that
mediate its physiological eﬀects, however, few direct
targets have been identiﬁed (42–44). One immediate
early G-CSF target is SOCS3, which upon activation
interacts with the tyrosine phosphorylated G-CSFR and
downregulates its signaling capacity (45–47).
In order to obtain insight into the regulation of MAD1
by G-CSF, we cloned the human MAD1 promoter region
and identiﬁed the elements relevant for the G-CSF
response. We observed that the JAK/STAT and the
RAS/RAF/ERK pathways contribute to the activation
of MAD1 through C/EBPb. Our ﬁndings suggest that
STAT3 is recruited to the promoter by binding to C/EBPb.
MATERIALS AND METHODS
Cellculture andtreatment conditions
HL60 (ATCC CCL-240) and U937 promyelocytes were
cultured in RPMI 1640 medium with 10% FCS. HEK293
and RK13 were cultured in DMEM and MEM medium,
respectively, with 10% FCS. The diﬀerent cell lines were
treated with 10ng/ml G-CSF (Chugai Pharmaceutical
Co., Ltd, Tokyo, Japan) for the indicated times.
Transient transfection andluciferase assay
RK-13 and HEK293 cells were transfected by the calcium
phosphate coprecipitation method as described previously
(48). For luciferase assays, 7–10mg of plasmids were
cotransfected. The cells were incubated for 24–28h in
complete medium and before harvesting treated with
10ng/ml G-CSF for 6h. The relative luciferase activities
were normalized to the b-galactosidase activities.
Cloning and expression constructs
All promoter mutant constructs were generated using the
QuickChange site-directed mutagenesis protocol
(Stratagene, Heidelberg, Germany) with complementary
primers spanning the mutation site, for veriﬁcation, all
mutated plasmids were sequenced. The expression vectors
pLNCX-GCSF/R pLNCX-GCSF/R649, pLNCX-
GCSF/R670, pLNCX-GCSF/R685 were obtained
from K. Welte (Hannover Medical School, Germany).
The expression constructs for the G-CSFR (pLNCX-
GCSF/RmA, pLNCX-GCSF/RmB, pLNCX-GCSF/
RmC, pLNCX-GCSF/RmD and pLNCX-GCSF/Rm0)
were provided by I. Touw (Rotterdam University,
The Netherlands) and have been described (38). The
cDNA of C/EBPa and b were cloned into CMV-
expression vector pCB6
+ (49). Human C/EBPe was
cloned into pcDNA3. The pCAGGS-neo-HA-STAT1,
pCAGGS-neo-HA-STAT3, pCAGGS-neo-HA-STAT3
(Y705F) and pECESTAT5a were provided by
G. Mu ¨ ller-Newen (RWTH Aachen University, Germany).
Western blot and immunoprecipitation
Whole-cell lysates were prepared on ice in F-buﬀer
[50mM HEPES, pH7.4, 50mM NaCl, 30mM Na4P2O7,
100mMN a 3VO4, 10% glycerol, 0.2% (w/v) Triton X-100,
1mM NaF] containing protease inhibitors. Cell extracts
were resolved by SDS–PAGE and transferred onto
nitrocellulose membranes. Blots were probed with the
indicated antibodies in PBS-T [0.1% (v/v) Tween-20/PBS],
washed and incubated with peroxidase-conjugated sec-
ondary antibodies. Detection was performed with the
chemiluminescence kit ECL (Amersham, Piscataway,
NJ, USA). For immunoprecipitation assays, whole-cell
extracts were incubated with 15ml protein A or G agarose
beads, and 2mg antibody rotating at 48C for 2h, washed
with F-buﬀer and speciﬁc proteins were identiﬁed by
western blot analysis.
Antibodies
Cytochrom C (Sc-7159, Santa Cruz), Polymerase II
(Sc-900, Santa Cruz), AcH3 (#06-866,Upstate), C/EBPa
(Sc-61, Santa Cruz), C/EBPb (Sc-746 and Sc-150, Santa
Cruz), C/EBPe (Sc-158, Santa Cruz), STAT3-P (#9131,
Cell Signaling), STAT3 (Sc-482, Santa Cruz), actin
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Chromatin immunoprecipitation assay (ChIP)
ChIP assays were performed in U937 cells as described
previously (50). The following primers were used: P1,
50-AGTTGCGAATCCTGTCACCA-30; P1’, 50-TTCTCT
TGACAGGCCAGCTT-30; G1, 50ATATTGTAGGTGA
CACAAACTGC-30; G1’, 50-ATCTCACTTGAAGCTTC
CACAG-30. These primer pairs ampliﬁed a 224bp and a
257bp product, respectively. PCR products were sepa-
rated on a 2% agarose gel using a 100bp DNA ladder as a
size marker (Fermentas).
Total RNA preparationand quantitative RT–PCR
Total cellular RNA was prepared using the RNeasy Mini
Kit (Qiagen) following the manufacturer’s instructions,
and residual genomic DNA was removed by DNase I
treatment (Qiagen). Total RNA (1.5mg) was reverse
transcribed to cDNA with Omniscript Reverse Transcrip-
tase (Omniscipt RT Kit, Qiagen) and analyzed by real
time PCR using TaqMan Universal PCR reagents with
ABI 7000 instrument (PE Applied Biosystems, Darmstadt,
Germany). The relative quantiﬁcation of MAD1 mRNA
was analyzed by the comparative CT method, and
normalized to that of -GLUCURONIDASE.
MAD1 probe 6-Fam-TGGACAGCATCGGCTCCA
CC-Tamra
MAD1-f 50-GAGAAGCTGGGCATTGAGAG-30
MAD1-r 50-ACGTCGATTTCTTCCCTGTC-30
-GLUCURONIDASE probe 6-Fam-TGAACAGTCA
CCGACGAGAGTGCTGG-Tamra
-GLUCURONIDASE-f 50-CTCATTTGGAATTTTG
CCGATT-30
-GLUCURONIDASE-r 50-CCGAGTGAAGATCC
CCTTTTTA-30
5’-RACE(rapid amplification of cDNA-ends)
U937 cells were grown to a density of 5 10
6 cells/ml and
stimulated with 10ng/ml human G-CSF for 2h. mRNA
was puriﬁed using the Oligotex mRNA-Kit (Qiagen)
according to the manufacturer’s instruction. For
50-RACE we used the 50/30-RACE-Kit (Roche) following
the manufacturer’s protocol. The 2mg of puriﬁed mRNA
were incubated with AMV-Reverse-Transcriptase and
speciﬁc primer Sp1 (50-CGGAGTCGGAGCGCTCCG)
to yield MAD1 cDNA. The single-stranded cDNA was
puriﬁed with High Pure PCR Puriﬁcation Kit (Roche).
The PCR reactions were preformed with the puriﬁed
cDNA as template and the oligo-dT-primer together with
the second speciﬁc primer Sp2 (50-AGCTGGTCGATT
TGGTGAACG). The oligo-dT-anchor-primer with the
third speciﬁc primer Sp3 (50-CACAAGCAAGATGAG
CCCG) were employed for the nested PCR reaction.
Ampliﬁed DNA was extracted from agarose gel using the
JetSorbKit (Genomed), cloned using the TA-cloning-kit
(Invitrogen) and sequenced (MWG Biotech). Alterna-
tively, the products of the reverse transcription with
primer Sp1 were analyzed further by PCR with Sp2 as
reverse primer and various forward primers from the
nucleosome mapping (described below). Quantiﬁcation of
the products was done by real time PCR.
Nucleosomal mapping
U937 cells were grown to a density of 5 10
5 cells/ml. The
cells were pelleted, washed two times in ice-cold PBS,
resuspended in TBS at a concentration of 2 10
7 cells/ml
and lyzed in TBS/1% Tween-20 (1:1) containing the
proteinase-inhibitor PefaBloc. The nuclei were resus-
pended in 1 TBS/25% sucrose (w/v) at a concentration
of 4 10
6 nuclei/ml and puriﬁed by sucrose-gradient
centrifugation (3000g,4 8C, 15min). The washed nuclei
were resuspended in digestion-buﬀer (0.32M sucrose,
50mM Tris–HCl pH7.5, 4mM MgCl2, 1mM CaCl2,
5mM Na-Butyrat pH8, PefaBloc). DNA-concentration
was photometically determined (Eppendorf). Fifty units of
Micrococcal Nuclease (MBI-Fermentas) were added per
0.5mg DNA and incubated at 378C for 5min. The
MNase-reaction was stopped by adding 0.5M EDTA
pH8 to a ﬁnal concentration of 5mM. The lysates were
centrifuged at 16000g for 15min. In parallel, input DNA
was soniﬁed (Branson Soniﬁer, Cell Disrubtor B15).
Puriﬁcation of DNA occurred by addition of proteinase
K (500mg/ml), RNAse (50ng/ml) and SDS to a ﬁnal
concentration of 0.25% and incubation at 378C for 6h.
Following phenol/chloroform extraction and isopropanol
precipitation, puriﬁed DNA was resuspended in TE-buﬀer
at pH7.5. PCR analysis was performed using 25 primer
pairs as indicated in Figure 4. The PCR products had an
average length of 100bp and overlapped by about 15 to
20bp. The PCR-program (30 cycles) was optimized and
adjusted for each primer pair. PCR products were
separated by agarose gel electrophoresis and quantiﬁed
using a Chemi-Doc-Documentation-System (BioRad).
The following primer sequences (forward, f; reverse, r)
were used (see Figure 4 for location within the MAD1
promoter fragment):
6f: 50-TACTGCAGCCCGATTCCAGC-30;
6r: 50-TTGAGAAGAAAAGCCGGCCG-30
7f: 50-TTCTTCTCAAGCCCCGCAGC-30;
7r: 50-TCCCGAAGAGCGGTGCAGG-30
8f: 50-AGCCTGCACCGCTCTTCGGG-30;
8r: 50-TGGTGGCCGCGGCCCTGG-30
9f: 50-TCCAGGGCCGCGGCCACC-30;
9r: 50-AATGGAAGGCTGGCACCTCG-30
10f: 50-AGGTGCCAGCCTTCCATTCG-30;
10r: 50-CCGGCCTTGCCTCGGACC-30
11f: 50-AGGTCCGAGGCAAGGCCG-30;
11r: 50-ATTGGCTGGGAGGGCCGG-30
12f: 50CGGCCCTCCCAGCCAATGC-30;
12r: 50-TTTCTCCAGGCCAGGCGAGC-30
13f: 50-TCGCCTGGCCTGGAGAAAGG-30;
13r: 50-AGAAGGCAAGCACCTCGCCG-30
14f: 50-GACCGGCGAGGTGCTTGC-30;
14r: 50-CCTTGTTTCCCATTGGTTCTATACC-30
15f: 50-GTTGTTGGTATAGAACCAATGGG-30;
15r: 50-GCTCCACCCCCTCTTTCC-30
16f: 50-TGGAAAGAGGGGGTGGAGC-30;
16r: 50-ACACTTGTGCGATTGGGAGAGG-30
17f: 50-AAGCCCTCTCCCAATCGCAC-30;
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18f: 50-AGCTGGCCTGTCAAGAGAAGG-30;
18r: 50-AGAGCAGCAGCCGCCACC-30
19f: 50-TGGCGGCTGCTGCTCTGC-30;
19r: 50-AACCACGCTCGACAAGAGAGG-30;
20f: 50-TCTCTTGTCGAGCGTGGTTGC-30;
20r: 50-AGCCCGCTATGGAGCCCGC-30;
21f: 50-AGCGGGCTCCATAGCGGGC-30;
21r: 50TGCACCGGGGGCCGGAGC-30
22f: 50-TCCCGTGGCTCCGGCCC-30;
22r: 50-CCGCCGCTCCAGATAGTCG-30
23f: 50-GACTATCTGGAGCGGCGGG-30;
23r: 50-TGAGGCCGGCCCCACAGG-30;
24f: 50-TGTGGGGCCGGCCTCAGG-30;
24r: 50-AGCCAGAGGGGTTGGGAGC-30
25f: 50-TCCCAACCCCTCTGGCTCTC-30;
25r: 50GCAGCCCCTTCTCCACCCC-30;
26f: 50-AATGAATGGGGTGGAGAAGGGG-30;
26r: 50-AGGCTATCGGAGGGGGC-30;
27f: 50GCCGGGGCCCCCTCCG-30;
27r: 50-AGACTGGGGCGCCGGGC-30;
28f: 50-CCCGGCGCCCCAGTCTCC-30;
28r: 50-ACCAGCTCAGGCGAAGGTGC-30
29f: 50-ACCTTCGCCTGAGCTGGTTC-30;
29r: 50-TGGCTAGGCTCACGCAGCC-30;
30f: 50-AGGCTGCGTGAGCCTAGCC-30;
30b: 50-AAATTGTGTGAATATCGTCAATTCGG-30
RESULTS
Characterization ofthe MAD1promoter
We observed previously that the MAD1 gene is activated
in the human promyelocytic cell line HL60 upon treat-
ment with G-CSF (32). We veriﬁed this activation in a
time course experiment by performing qRT–PCR analy-
sis. G-CSF induced MAD1 expression in HL60 cells to a
similar extend and with similar kinetics as TPA
(Figure 1A). Similarly, G-CSF induced MAD1 in the
human promyelocytic line U937 as analyzed by northern
blot (Figure 1B). The stimulation was insensitive to
cycloheximide and was also observed by qRT–PCR
(Figure 1B and C). These ﬁndings suggested that MAD1
expression is regulated by G-CSF independent of de novo
protein synthesis. An important signal transducer of the
G-CSFR is STAT3 that is activated in response to G-CSF.
Indeed, in both U937 and HL60 cells phosphorylation
of STAT3at Tyr705 is enhanced by G-CSF (Figure 1D
and data not shown).
In order to study the regulation of MAD1 by G-CSF in
more detail, we cloned the human MAD1 promoter.
The MAD1 gene spans over 23 kbp and extends over 6
exons (alternatively 7 exons) on chromsome 2p13-p12
(Figure 2A, HTGS Acc. No. AC019206). Upstream of the
most 50 mRNA human MAD1 sequence, we identiﬁed a
GC-rich region of about 400bp that revealed a high
degree of sequence homology to murine and rat mad1
(Figure 2B). In the following, we refer to this sequence
as the homology region (Figure 3A). To determine
whether the transcriptional start site(s) (TSS) is located
within this region, we performed 50-RACE experiments.
Originally we cloned two products that indicated a major
TSS at –250 and one at –46 relative to the translational
initiation site (Figure 2C). The former is located within
the homology region and was used subsequently for
the numbering of the MAD1 promoter (Figure 2B).
Additional 50RACE analysis and comparison with the
50-ends of MAD1 clones available in the data base
suggested that multiple TSS are used, primarily down-
stream of the -250 site. This was further supported by
the analysis of the primary 50-RACE products. These
were ampliﬁed with the Sp2 reverse primer and several
forward primers using quantitative PCR (Figure 2D).
A sharp increase in the amount of product was observed
between primers 18 and 19, which ﬂank the major TSS
(Figure 2B and D). Primer 20, which is located further 30,
showed an increase compared to primer 19, while primer
22, which is close to the ATG of the TSS, revealed little
additional product (Figure 2D). A primer located at
the beginning of intron 1 was used for control but gave
no signal (data not shown). Together, these ﬁndings are
consistent with multiple TSS, comparable to what has
been reported for other CpG-island promoters (the
number of CpG dinucleotides is given in the legend to
Figure 2) (51).
MAD1 reporter gene constructs areG-CSF/G-CSFR
responsive
The functionality of the putative MAD1 promoter was
addressed experimentally by cloning diﬀerent portions
into the pGL2 luciferase vector and analyzing the
activities of these reporter gene constructs in RK13 cells
(Figure 3A). We observed that constructs with at least
the 30 half of the homology region possessed promoter
activity as compared to the pGL2 control (Figure 3B).
Shorter constructs beginning at –58, +64 and +131
(the numbers deﬁne nucleotides relative to the 50 start site
of transcription) and the isolated homology region from –
385 to +25 showed little basal activity (Figure 3B). Thus
sequences within the homology and the 50 untranslated
region seem to be necessary for basal promoter activity
(Figure 3B). These ﬁndings are in agreement with the
mapping of the start of transcription. Next we determined
the G-CSF-responsiveness of the diﬀerent MAD1 promo-
ter constructs. RK13 cells do not respond to human
G-CSF and therefore human G-CSFR was co-expressed.
This resulted in weak activation, probably due to
dimerization and auto-activation (Figure 3C). The largest
MAD1 promoter fragment (–1282 to+248) was activated
roughly 3-fold (Figure 3A and B). However, deletion of
 500bp (resulting in –795 to+248) substantially
enhanced the response to G-CSF/G-CSFR indicating
that this distal promoter region contains negative regula-
tory elements. A high level of activation by G-CSF/G-
CSFR was maintained with several MAD1 promoter
fragments including the region from –184 to +248
(Figure 3). Deletion of a further 126bp (in –58 to +248)
substantially reduced and deletion beyond the start site
of transcription abolished the G-CSF/G-CSFR response.
A reporter gene construct with the isolated homology
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level of activity upon stimulation with G-CSF/G-CSFR
(Figure 3A and B). The ﬁndings above suggested that the
region from –184 to –58 within the homology domain
contains the G-CSF/G-CSFR responsive elements. To
verify this conclusion, the –184 to –58 fragments were
cloned into a reporter construct with a minimal core
promoter of the thymidine kinase gene (mintk-luc). This
MAD1 promoter fragment was suﬃcient to confer
G-CSF/G-CSFR responsiveness to the minimal tk pro-
moter (–184/–58-mintk-luc) (Figure 3D). Together, these
data deﬁne the MAD1 core promoter and a segment of the
homology region that mediates the G-CSF/G-CSFR
response.
The homologyregion shows distinctchromatin organization
To further evaluate the MAD1 promoter, we performed
ChIP experiments. In the absence of G-CSF, the MAD1
promoter was occupied by RNA-polymerase II (Pol II)
in U937 cells (Figure 4A). In contrast, no Pol II binding
was seen within the gene body. This ﬁnding provided
further evidence that the 30 half of the homology region
contains the core promoter. Upon G-CSF stimulation
Pol II loading remained constant on the core promoter,
but Pol II binding was now apparent further downstream
(Figure 4A). This observation suggested that G-CSF
induced MAD1 transcription by activating pre-assembled
Pol II.
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Figure 1. The MAD1 gene is regulated by G-CSF. (A) Exponentially growing HL60 promyelocytic cells were treated with the phorbol ester TPA
(1.6 10
–8M) or recombinant G-CSF (10ng/ml) for the indicated times. MAD1 mRNA was quantiﬁed by qRT–PCR with b-GUS as the internal
standard. Mean values and standard deviations of three independent experiments are shown. (B) Exponentially growing U937 promyelocytic cells
were treated as described in (A). Cycloheximide (25mM) was added 15min prior to treatment with G-CSF. Total RNA was extracted, 15mg/lane
separated on a formaldehyde–agarose gel and blotted. The hybridization was performed with probes speciﬁc for human MAD1 and MYC. The two
distinct MAD1 mRNA species observed are roughly 3.8 and 6.0kb long and are most likely the result of alternative splicing in exon 6, 30 of the open
reading fame, creating an additional non-coding exon 7. For loading control, the ethidium bromide-stained gel is shown with the 28S and 18S
ribosomal RNAs indicated. (C) The experiments were performed as in (A) and (B). A qRT–PCR analysis of MAD1 mRNA is displayed. The mean
values and standard deviations of three independent experiments performed in duplicates are shown. (D) U937 cells were stimulated with G-CSF
(10ng/ml) for the indicated times, total cell lysates generated in RIPA buﬀer and the samples immunoblotted for STAT3 (lower panel) and for
Tyr705 phosphorylated STAT3 (upper panel).
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Figure 2. Identiﬁcation of the putative promoter region of MAD1.( A) The genomic organization of human MAD1 was deduced from comparing the
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deviations of two independent experiments performed in duplicates are displayed.
1522 Nucleic Acids Research, 2008, Vol. 36, No. 5Since Pol II was occupying the MAD1 promoter prior
to G-CSF stimulation, we analyzed the chromatin
organization of this promoter. Nuclei of U937 cells were
treated with micrococcal nuclease (MNase) to generate
nucleosomal-sized DNA fragments (Figure 4B). This
DNA was then analyzed by PCR using primers that
ampliﬁed overlapping fragments of about 100bp of the
MAD1 promoter. The protection against MNase was poor
over the core of the homology region spanning about 250
to 300bp, while the neighboring portions of the promoter
were well protected (Figure 4C). This suggested that the
homology region contained either low number of nucleo-
somes or that the nucleosomes were poorly positioned. In
ChIP experiments, acetylated histone H3 was associated
with the homology region (Figure 4A). However, the
poorly protected region is most likely too small to be
separated clearly from neighboring promoter chromatin
by ChIP. In summary, these ﬁndings demonstrate that the
G-CSF-responsive region of the MAD1 promoter shows
distinct chromatin organization. Next, we addressed
whether G-CSF signaling aﬀected chromatin organization
at the MAD1 promoter. G-CSF did not appreciably aﬀect
the extent of histone H3 acetylation in U937 cells
(Figure 4A). Furthermore, neither G-CSF nor TPA
treatment changed the sensitivity of the MAD1 promoter
to MNase (Figure 4D). From these experiments it
appeared that the chromatin organization did not
change grossly during stimulation of MAD1 expression.
G-CSFR signaltransduction pathways that
mediate MAD1 activation
G-CSFR signaling is mediated by proteins recruited to
the region proximal to the transmembrane domain and,
upon phosphorylation, through four tyrosine residues
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Figure 3. The MAD1 promoter is activated by G-CSF. (A) Schematic representation of the MAD1 promoter fragments that were cloned into pGL2.
The homology region that shows high sequence conservation between human, mouse and rat is indicated. Furthermore, the major start sites of
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Nucleic Acids Research, 2008, Vol. 36, No. 5 1523(Y704, Y729, Y744 and Y764, summarized in Figure 5A)
(35,36). To address the role of these elements for signaling
to the MAD1 promoter, we used receptor deletion
mutants. Loss of the distal region of the cytoplasmic
portion of the G-CSFR in three diﬀerent deletion mutants
(52), including all four tyrosine residues, completely
abolished stimulation of the –184 to +248 MAD1
promoter construct (Figure 5B). This suggested that the
Tyr residues might be critical to mediate the signaling to
the MAD1 promoter. Therefore, we used G-CSFR
mutants, in which only a single tyrosine residue was
maintained while the others were mutated to phenylala-
nine (41). We observed that when either only Y704 or only
Y744 was present (lacking the SOCS3-binding sites that
mediates repression), stimulation was more pronounced
than with the wild-type (wt) G-CSFR (Figure 5C).
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1524 Nucleic Acids Research, 2008, Vol. 36, No. 5These studies were complemented with G-CSFR mutants,
in which individual tyrosines were mutated to phenylala-
nine (41). Indeed, the role of Y704, the major STAT3-
binding site, was further substantiated. Mutation of this
tyrosine in G-CSFR(Y704F) was suﬃcient to signiﬁcantly
reduce activation of the MAD1 promoter construct
(Figure 5D). In contrast, mutation of Y744 had little
consequence (Figure 5D), consistent with the ﬁnding that
through this tyrosine STAT3 can be activated but to
a lesser degree than through Y704 (41). These ﬁndings
suggest that eﬃcient activation of STAT3 is important to
stimulate the MAD1 promoter.
A receptor mutant with only Y764 showed comparable
activity to wt G-CSFR (Figure 5C). However, loss of
this tyrosine in G-CSFR(Y764F) was not suﬃcient to
reduce the stimulatory eﬀect on the MAD1 promoter
(Figure 5D), indicating that most likely alternative
mechanisms exist to activate the MAPK and/or
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Figure 5. STAT3 is important to activate the MAD1 promoter. (A) Schematic representation of the cytoplasmic portion of the G-CSF receptor
(G-CSFR). The conserved boxes 1–3 and the four tyrosine residues that are known to be phosphorylated in response to G-CSF are indicated.
The signal transduction pathways that are connected to the individual tyrosine residues are given. (B) RK13 cells were cotransfected with the –184
to+248 MAD1 promoter luciferase reporter construct and expression plasmids for the indicated wild-type G-CSFR or deletion mutants. The cells
were stimulated with G-CSF prior to harvesting and measuring luciferase and b-galactosidase activity. A typical experiment performed in triplicates
is shown. (C and D) The experimental design was as in (B). G-CSFR mutants with the indicated changes of either individual tyrosine residues or
combination of tyrosines were analyzed. (E) The transfections were performed as in panel B with the additional co-expression of diﬀerent STAT
factors as indicated. A typical experiment performed in duplicates is shown. (F) The experiment was done as in panel B. A dominant negative version
of STAT3 [STAT3(Y705F)] was co-expressed as indicated.
Nucleic Acids Research, 2008, Vol. 36, No. 5 1525PI3K/AKT signal transduction pathways. In contrast to
the other Tyr residues, when only Y729 was present
substantially reduced MAD1 promoter stimulation was
observed (Figure 5C), while G-CSFR(Y729F) was sub-
stantially more active (Figure 5D). Thus it appears that
Y729, which recruits the suppressor of cytokine signaling
(SOCS) 3, is mainly involved in signal repression, as
suggested before, and demonstrated here by the strong
eﬀects on MAD1 promoter activity.
Y704 and Y744 are implicated in recruiting STAT3. This
is supported by the analysis of the diﬀerent G-CSFR
mutants in combination with MAD1 promoter analysis.
Indeed co-expression of STAT3, but not other STATs,
was suﬃcient to enhance the G-CSF/G-CSFR response
of the –184 to +248 MAD1 promoter reporter construct
(Figure 5E). Furthermore, co-expression of a dominant
negative mutant of STAT3 (STAT3(Y705F)) that cannot
be phosphorylated on this tyrosine was suﬃcient to reduce
the G-CSF/G-CSFR-dependent activation of the –184/
+248-luc or of the –184/–58-mintk-luc reporter gene
constructs (Figure 5F and data not shown). Similarly, the
activities of G-CSFR mutants with only one Tyr residue,
i.e. Y704 or Y744, were sensitive to STAT3(Y705F)
(Figure 5F). The G-CSFR mutant with only Y764 was
weakly sensitive to STAT3(Y705F), possibly a conse-
quence of the reported tyrosine-independent activation
of STAT3 by G-CSFR [41,53]. In summary, these
observations support the notion that STAT3 is an
important downstream mediator of the G-CSFR in the
activation of the MAD1 promoter.
The C/EBPresponse elements are importantto activate
theMAD1 promoter inresponse to G-CSF/G-CSFR
Since Y704 of the G-CSFR was suﬃcient to mediate
MAD1 promoter activity, STAT3 appeared to be impor-
tant. However, inspection of the –184 to+248 MAD1
promoter sequence did not reveal any STAT consensus
DNA-binding site. However, we noticed two CCAAT-
boxes that can serve as binding sites for C/EBP factors
(Figures 2B and 6A). These proteins are involved in
regulating diﬀerentiation processes (54,55). In addition,
a GC-box is present in the G-CSF/G-CSFR responsive
region of the homology domain (Figures 2B and 6A).
These elements are recognized by transcription factors
of the SP family and are commonly found in CpG-island
promoters, mediating basal activity in many instances
(56,57). To address whether these sites might be important
to mediate the G-CSF/G-CSFR eﬀect, we mutated
the CCAAT-boxes and the GC-box either individually
or in combination (Figure 6A). These mutations reduced
the basal promoter activity but aﬀected the G-CSF
responsiveness more severely (Figure 6B and C). While
mutating the GC-box had little eﬀect, the loss of the
two CCAAT-boxes reduced substantially the response to
G-CSF/G-CSFR of the –184 to+248 MAD1 promoter
fragment (Figure 6C). When all three sites were mutated
the promoter fragment was only poorly stimulated by
G-CSF/G-CSFR. To determine whether these three sites
were also relevant in combination with an unrelated
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1526 Nucleic Acids Research, 2008, Vol. 36, No. 5core promoter, the mutants were introduced into the
–184/–58-mintk-luc reporter. Similar to the ﬁndings with
the MAD1 promoter, these mutations aﬀected both
basal as well as stimulated activity (Figure 6D and E).
In particular, mutating the two CCAAT-boxes reduced
the eﬀect by G-CSF/G-CSFR (Figure 6E). In combination
with the tk promoter, loss of the GC-box also aﬀected
G-CSF signaling. When all three sites were mutated
little stimulation was observed (Figure 6E). To verify the
ﬁndings described earlier, we compared the stimulation
by G-CSF/G-CSFR of the –184 to+248 promoter
fragment with the corresponding fragment mutated at
the two CCAAT-boxes and at the GC-box. In addition,
we included a MAD1 promoter fragment without the
responsive region (–58 to+248) and the luciferase vector
without a promoter. Mutation of the three sites resulted
in a strong reduction in the responsiveness to G-CSF/
G-CSFR with the remaining activity being comparable
to the fragment without responsive region (Figure 6F).
Both constructs still revealed a small but reproducible
stimulation by G-CSF/G-CSFR (Figure 3). In summary,
these ﬁndings suggested that the three conserved sites,
the two CCAAT-boxes and to a lesser extent the
GC-box, mediate a substantial part of the G-CSF/
G-CSFR-response that controls the MAD1 promoter.
C/EBP transcription factorsdirectly regulate
the MAD1promoter and interact with STAT3
To address the role of CCAAT-box binding factors, we
analyzed the eﬀect of diﬀerent C/EBP proteins on MAD1
reporter genes. Of the three tested C/EBP proteins,
C/EBPa and C/EBPb activated the –184 to+248 MAD1
promoter fragment strongly, while C/EBPe was a poor
stimulator (Figure 7A). This indicated that C/EBP factors
might be involved in regulating the MAD1 promoter.
Therefore, we tested whether these proteins could interact
with the promoter in cells. U937 cells were stimulated with
G-CSF, subsequently crosslinked and the binding of C/
EBPa, b and all three are expressed in U937 cells (data not
shown), to the MAD1 promoter was analyzed by ChIP.
Near the core promoter, C/EBPa and C/EBPb were
constitutively bound while no interaction with C/EBPe
could be seen. In response to G-CSF, a shift from
preferentially C/EBPa to C/EBPb was detected
(Figure 7B). We further analyzed C/EBPb and observed
that stimulation of the MAD1 promoter was dependent
on the two CCAAT-boxes with both elements contribut-
ing roughly equally to C/EBPb-mediated activation
(Figure 7C). Similarly in the context of the minimal tk
promoter, both CCAAT-boxes were relevant and, in
addition, also the GC-box (Figure 7D). Of note is that
SP1 interacted with the MAD1 promoter by ChIP but
the expression of wt or dominant negative SP1 had little
eﬀect on MAD1 reporter gene constructs (data not
shown). Thus C/EBP transcription factors and their
response elements are involved in regulating the MAD1
promoter.
The results described earlier suggest that the G-CSF/
G-CSFR response is mediated at least in part by STAT3.
Since no obvious STAT3-binding sites could be detected,
we evaluated whether C/EBPb and STAT3 could interact.
We expressed the two proteins in HEK293 cells in the
presence of G-CSFR. The cells were then stimulated with
G-CSF, low stringency lysates prepared and C/EBPb
immunoprecipitated. STAT3 was co-immunoprecipitated
only when the cells were stimulated with G-CSF
(Figure 7E). In addition, the signal dependency of the
interaction of STAT3 with C/EBPb was assessed by using
G-CSFR mutants. With only Y704 present, which is
responsible for STAT3 activation, the interaction of
STAT3 with C/EBPb was 3-fold weaker than with the
wt receptor (Figure 7F). In contrast, a receptor with
only Y764 did not stimulate the interaction between
STAT3 and C/EBPb. The interaction was weak indicat-
ing that it might be highly transient, providing an
explanation for the lack of STAT3-binding sites in the
MAD1 promoter. Thus, we propose that STAT3 is
recruited by C/EBPb to the MAD1 promoter.
DISCUSSION
We have identiﬁed the promoter of the MAD1 transcrip-
tional repressor. Diﬀerential expression of MAD1 and
the other small MAD genes and proteins has been well
documented in diﬀerent tissues and during development
(7). However, relatively little is known about how these
expression patterns are controlled. The analysis of the
MAD1 promoter in U937 cells revealed an unexpected
chromatin organization (Figure 4). The MNase analysis
allowed us to identify a region of chromatin that
was highly accessible to nuclease treatment. This region
overlapped with the homology region, a promoter
sequence that is highly conserved between human, rat
and mouse and has the hallmarks of a CpG-island (56).
What is common to all four MAD gene promoters, here
shown for MAD1, is that they are TATA-less and contain
GC-rich regions (58–60). SP transcription factors are
frequently associated with GC-rich promoters, where
they fulﬁll basal activities, but they can also be the
target of signal transduction pathways (56,57). SP1 was
described as a critical factor to control the expression of
the MXI1 gene (58). SP1 was also found associated with
the MAD1 promoter, as determined by ChIP experiments,
and interacted with the GC-boxes in electrophoretic
mobility shift experiments (data not shown). However,
the manipulation of SP1 or SP3 activity did not have
substantial eﬀects on the MAD1 promoter reporter
gene constructs used in this study (data not shown).
These ﬁndings are consistent with a basal activity
of the GC-boxes and associated SP factors (56,57).
the G-CSFR. The stimulation by G-CSF/G-CSFR is shown on
diﬀerent –184 to +248 MAD1 promoter reporter gene constructs
that are mutated in either the C/EBP-binding sites and/or in the
GC-box. The mean values and standard deviations of three experiments
performed in duplicates are displayed. (D) The experiments were
performed as in panel B but with the –184 to –58 MAD1 promoter
region cloned 50 of the minimal tk promoter. (E) The experiments were
as in panel C with the exception that the –184 to –58 region of the
MAD1 promoter, and mutants thereof, were tested in combination with
the mintk promoter. (F) The experimental design was as in (C). A
typical experiment performed in duplicates is displayed.
Nucleic Acids Research, 2008, Vol. 36, No. 5 1527The promoter of the murine mad3 gene also contains
potential binding sites for SP factors but no evidence for
their involvement in mad3 expression has been found (59).
Unlike the other MAD genes, mad3 is also expressed in
some cycling cells, peaking in S-phase (21,61). E2F1, a
member of the E2F family of cell cycle regulators (62),
binds to the mad3 promoter and regulates its cell cycle-
speciﬁc expression. The response element for E2F factors
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Figure 7. C/EBP proteins regulate the MAD1 promoter. (A) The –184 to+248 MAD1 promoter reporter gene construct was cotransfected with plasmids
expressing diﬀerent C/EBP proteins. The mean values and standard deviations of three experiments performed in duplicates are shown. (B) U937 cells
were stimulated for the indicated times with G-CSF. The cells were then crosslinked, lyzed and the indicated proteins immunoprecipitated. The associated
DNA was analyzed by PCR using primers that correspond to the 30 portion of the homology region or to a downstream fragment within the MAD1 gene
body. For control serial dilutions of input DNA was analyzed by PCR. (C) Transient transfections were performed as described in (A). Reporter
constructs with the indicated mutations were used as shown. (D) Transient transfections were performed as described (A) with –184 to –58-mintk
promoter constructs and mutants thereof. (E) C/EBPb, HA-STAT3 and G-CSFR were expressed in HEK293 cells. Prior to harvesting, the cells were
treated with or without G-CSF as indicated. C/EBPb was immunoprecipitated and the associated STAT3 detected by western blotting using an antibody
speciﬁc for the HA-tag. The lysates show the expression controls. (F) The experimental approach was as in panel E. The relative STAT3 interaction with
C/EBPb upon stimulation with G-CSF and the indicated receptor mutants is displayed.
1528 Nucleic Acids Research, 2008, Vol. 36, No. 5is also conserved in the human MAD3 gene, suggesting
that its regulation is also controlled by E2F (59).
The murine mad4 promoter is activated during diﬀerentia-
tion. Here an initiator sequence element was found to be
critical to repress mad4 in proliferating cells. This element
is controlled by the MIZ1/MYC complex (60). MYC was
previously identiﬁed as a repressing cofactor of MIZ1,
providing a molecular explanation how MYC represses
gene transcription (1). Together, these studies deﬁne
various transcription factors and signaling pathways that
control the expression of the four MAD genes. As
expected from the overlapping but also distinct expression
patterns observed, both common and distinct regulatory
factors are associated with the diﬀerent genes. The
common factors could include SP proteins that might be
relevant for the broad expression pattern of individual
genes. In addition, speciﬁc factors might determine
the expression in a cell-type and signal-speciﬁc fashion.
E2Fs for mad3 and C/EBPs for MAD1 provide examples
for the latter. Nevertheless, we assume that the GC-boxes
are of functional relevance since their mutation reduces
basal promoter activity and since they contribute to C/
EBP-dependent gene activation (Figures 6 and 7).
Interestingly, Pol II was bound to the promoter
constitutively, suggesting that in U937 the MAD1
promoter is in a pre-active state. In this state, the
incoming G-CSF/G-CSFR signals rapidly increase pro-
moter activity by stimulating STAT3 activity and most
likely the RAS/RAF/ERK pathway that controls the
activity of C/EBP transcription factors. The C/EBP
proteins, similar to Pol II, were constitutively bound to
the MAD1 promoter. Whether this is consistent with the
presence of an enhanceosome (63), potentially with SP and
C/EBP factors at its core, remains to be addressed.
The mutagenesis of the MAD1 promoter suggested
strongly that the CCAAT-boxes are critical to mediate the
G-CSF/G-CSFR response (Figures 6). C/EBP transcrip-
tional regulators are involved in the regulation of
proliferation and diﬀerentiation in many diﬀerent cell
types and function as executors of lineage commitment
(54,55). In particular, C/EBP proteins have been demon-
strated to be involved in the control of myeloid
and granulocytic cell physiology. Four members of the
family (a, b, d and e) are expressed in myeloid cells (54).
C/EBPa is downregulated during terminal granulocytic
diﬀerentiation (64), an observation that is in agreement
with the loss of C/EBPa interaction to the MAD1
promoter in response to G-CSF (Figure 7). The impor-
tance of this C/EBP member is also documented by the
observation that c/ebp
–/– mice fail to undergo myeloid
diﬀerentiation and lack neutrophils (65). In addition,
C/EBPe was suggested to be important for granulopoiesis
since this factor is preferentially expressed during granu-
locytic diﬀerentiation (66,67). Although this factor is
expressed in U937 cells (data not shown), we could not
detect it on the MAD1 promoter and it was a poor
activator of the MAD1 reporter genes (Figure 7).
Similarly, C/EBPd could not activate the MAD1 reporter
genes (data not shown). The fourth C/EBP family member
analyzed, C/EBPb, was capable to activate the MAD1
reporter genes in a CCAAT-box-dependent manner and
bound to the promoter in cells (Figure 7). C/EBPb is not
essential for myeloid development in the mouse (68).
However, recent ﬁndings indicate that C/EBPb-deﬁcient
neutrophils display enhanced apoptosis (69). A role of
C/EBPb in controlling MAD1 expression is in line with
the anti-apoptotic function of this protein (20,24,26). Thus
C/EBP factors, and in particular C/EBPb, appear to be
important to control diﬀerent aspects of myeloid cell
physiology. Since our ChIP experiments revealed that
both C/EBPa and C/EBPb are bound to the MAD1
promoter, it is possible that these proteins function as
homo- or heterodimers in controlling promoter activity.
We note however that the two CCAAT boxes represent
only ‘half-sites’ and binding of C/EBPb to these sites in
electrophoretic mobility shift experiments is poor (data
not shown). Thus it is possible that additional factors are
required for eﬃcient binding of C/EBP proteins to the
proposed sites in the MAD1 promoter.
Nevertheless, the mutation of the CCAAT-boxes
reduced substantially the responsiveness to G-CSF/
G-CSFR; our ﬁndings suggest that C/EBP proteins are
critical for the activation of the MAD1 promoter. Since
STAT3 seems to be relevant as well, but no binding sites
could be found in the responsive promoter fragment, and
since we failed to detect STAT3 in ChIP experiments
on the promoter, we suggest that STAT3 is recruited
by C/EBP proteins to the promoter. Indeed, we observed
co-immunoprecipitation of the two proteins when over-
expressed and stimulated with G-CSF/G-CSFR
(Figure 7). Probably owing to the weak interaction and
possibly the transient nature of this complex, we were
unable to detect this complex with endogenous proteins.
This model is in agreement with a recent study that
showed interaction of STAT3 with C/EBPa in response
to G-CSF/G-CSFR (70). These authors ﬁnd that a
synthetic C/EBPa reporter is stimulated by STAT3.
Thus, it appears that diﬀerent C/EBP factors can interact
with STAT factors and cooperate in gene activation.
These ﬁndings suggest that STAT3 functions as cofactor
in these circumstances. In the future the relevance of the
activity of STAT3 in various settings, including tumor
formation, will be important to investigate.
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